Physician profile
Jonathan Pearlstein
NPI 1871563403
$4,908.29
in general payments reported to CMS, 2019-2025
34 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,180 · 2020: $726 · 2021: $450 · 2022: $139 · 2023: $343 · 2024: $791 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $702.97 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $604.02 | 2019-2022 | |
| Amgen INC. | $491.63 | 2019-2024 | Aimovig |
| Ucb, INC. | $459.37 | 2019-2025 | Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $317.16 | 2019-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $266.51 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $261.58 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $243.48 | 2019-2024 | Austedo Xr, Austedo |
| Biogen, INC. | $226.31 | 2019-2024 | Avonex, Vumerity |
| Lilly USA, LLC | $163.87 | 2019-2020 | |
| Genzyme Corporation | $154.12 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $150.96 | 2019 | |
| Amneal Pharmaceuticals LLC | $116.67 | 2019-2024 | Rytary |
| Pfizer INC. | $71.67 | 2023-2024 | |
| Mdd US Operations, LLC | $68.10 | 2019-2024 | Gocovri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $63.68 | 2024 | Nuedexta |
| Acadia Pharmaceuticals INC | $57.51 | 2019-2024 | Nuplazid |
| Sumitomo Pharma America, INC. | $52.77 | 2023-2024 | Aptiom |
| Csl Behring | $47.08 | 2019 | |
| Emd Serono, INC. | $46.48 | 2019 | |
| Upsher-Smith Laboratories LLC | $44.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $32.99 | 2020 | |
| Promius Pharma LLC | $31.98 | 2019 | |
| Adamas Pharmaceuticals, INC. | $31.36 | 2019 | |
| Allergan, INC. | $26.14 | 2019 | |
| Kyowa Kirin, INC. | $25.95 | 2020 | |
| Nevro Corp. | $24.98 | 2023 | Senza |
| Lundbeck LLC | $24.81 | 2024 | Vyepti |
| Argenx US, INC. | $17.87 | 2024 | Vyvgart Hytrulo |
| Grifols USA, LLC | $17.78 | 2024 | Gamunex-C |
| Acorda Therapeutics, INC | $17.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.82 | 2020 | |
| Sk Life Science, INC. | $15.81 | 2020 | |
| Assertio Therapeutics, INC. | $14.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pearlstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.